Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Harvard Business School
AstraZeneca
McKinsey
Johnson and Johnson

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,748,475

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,748,475
Title:Methods and compositions for treating lupus
Abstract: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases.
Inventor(s): Wang; Longgui (Flushing, NY), Mencher; Simon K. (New York, NY)
Assignee: Natrogen Therapeutics International, Inc. (New York, NY)
Application Number:13/197,164
Patent Claims:1. A method of treating an animal with lupus nephritis, the method comprising the step of administering to the animal in need of such treatment at least one compound selected from the group of: Meisoindigo, tri-acetylated glyco-Meisoindigo (pro-drug) or 1-(.beta.-D-O-triacetyl-xylopyranosyl)-isoindigo, shown as Formulas (IV), (V), and (VI) respectively, ##STR00002## wherein the compound is administered in an amount sufficient to treat lupus nephritis.

2. The method according to claim 1, wherein the amount administered is sufficient to inhibit pro-inflammatory cytokine expression and/or stimulate anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.

3. The method according to claim 1, wherein the amount administered is less than about 0.36 mmol/kg per day.

4. The method according to claim 3, wherein the compound administered is Meisoindigo and the amount administered is less than about 100 mg/kg per day.

5. The method according to claim 3, wherein the amount administered is between 0.036 mmol/kg and 0.288 mmol/kg per day.

6. The method according to claim 4, wherein the amount administered is between 10 mg and 80 mg per day.

7. The method according to claim 1, wherein the animal is a human.

8. The method according to claim 2, wherein the compound is administered in an amount sufficient to inhibit cytokine IL-1.alpha., .beta., IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-.alpha., LT, LIF, Oncostatin, or IFNc1.alpha., .beta., .gamma..

9. The method according to claim 2, where the compound is administered in an amount sufficient to stimulate expression of cytokine IL-4, IL-10, IL-11, W-13 or TGF.beta..

10. The method according to claim 2, where the compound is administered in an amount sufficient to modulate cytokines TNF-.alpha., IL-1.beta., IL-6, and IL-10.

11. The method according to claim 1, where the compound is administered in an amount sufficient to reduce proteinuria levels and/or sufficient to modulate a humoral response.

12. The method according to claim 11, wherein modulation of a humoral response includes a decrease in total IgG antibody within the animal.

13. A method of treating lupus nephritis, the method comprising the step of administering to an animal in need of such treatment at least a first and a second compound, wherein the first compound is selected from the group of: Meisoindigo, tri-acetylated glyco-Meisoindigo (pro-drug) or 1-(.beta.-D-O-triacetyl-xylopyranosyl)-isoindigo, shown as Formulas (IV), (V), and (VI) respectively, ##STR00003## wherein the second compound is selected from the group consisting of: anti-inflammatory agent, corticosteroid, immune suppressant, or biologic drug; and wherein the first compound is administered in an amount sufficient to treat lupus nephritis.

14. The method according to claim 13, wherein the first compound is administered in an amount sufficient to inhibit pro-inflammatory cytokine expression and/or stimulate anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.

15. The method according to claim 13, wherein the compounds are administered concurrently within a single composition.

16. The method according to claim 13, wherein the compounds are administered sequentially.

17. The method according to claim 13, wherein the second compound is selected from the group of: ibuprofen, corticosteroid, methotrexate, or BLyS-specific inhibitors.

18. The method according to claim 17, wherein the BLyS-specific inhibitor is belimumab.

19. The method according to claim 13, wherein the first compound is administered in an amount less than about 0.36 mmol/kg per day.

20. The method of claim 17, wherein the first compound is administered in an amount between 0.036 mmol/kg and 0.288 mmol/kg per day.

21. The method according to claim 13, wherein the animal is a human.

22. The method according to claim 13, wherein the first compound is administered in an amount sufficient to inhibit cytokine IL-1.alpha., .beta., IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-.alpha., LT, LIF, Oncostatin, or IFNc1.alpha., .beta., .gamma.; and/or sufficient to stimulate expression of cytokine IL-4, IL-10, IL-11, W-13 or TGF.beta..

23. The method according to claim 13, where the first compound is administered in an amount sufficient to modulate cytokines TNF-.alpha., IL-1.beta., IL-6, and IL-10.

24. The method according to claim 13, where the first compound is administered in an amount sufficient to reduce proteinuria levels and/or sufficient to modulate a humoral response.

25. The method according to claim 24, wherein modulation of a humoral response includes a decrease in total IgG antibody within the animal.

26. A composition for treating lupus nephritis, the compositions comprising an active compound, an agent, and a pharmaceutically acceptable carrier, wherein the active compound is selected from the group of: Meisoindigo, tri-acetylated glyco-Meisoindigo (pro-drug) or 1-(.beta.-D-O-triacetyl-xylopyranosyl)-isoindigo, shown as Formulas (IV), (V), and (VI) respectively, ##STR00004## and the agent is selected from the group consisting of: an anti-inflammatory agent, corticosteroid agent, immune suppressant agent, or a biologic drug.

27. The composition of claim 26, wherein the anti-inflammatory agent is ibuprofen, the immune suppressant agent is methotrexate, and the biologic drug is a BLyS-specific inhibitor.

28. The composition of claim 27, wherein the BLyS-specific inhibitor is belimumab.

29. A method of treating an animal with nephritis, the method comprising the step of administering to the animal in need of such treatment at least one compound selected from the group of: Meisoindigo, tri-acetylated glyco-Meisoindigo (pro-drug) or 1-(.beta.-D-O-triacetyl-xylopyranosyl)-isoindigo, shown as Formulas (IV), (V), and (VI) respectively, ##STR00005## wherein the compound is administered is in an amount sufficient to treat nephritis.

30. The method of claim 27, wherein the nephritis is glomerulonephritis.

Details for Patent 8,748,475

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Llc BENLYSTA belimumab For Injection 125370 2011-03-09 ⤷  Sign up for a Free Trial 2024-01-12
Glaxosmithkline Llc BENLYSTA belimumab Injection 761043 2017-07-20 ⤷  Sign up for a Free Trial 2024-01-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.